Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00155168 |
|
Recruitment Status : Unknown
Verified April 2004 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : September 12, 2005
Last Update Posted : September 12, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Spinal Muscular Atrophy |
Proximal spinal muscular atrophy is an autosomal recessive disorder with an overall incidence of 1 in 10000 live births and a carrier frequency of 1 in 50. This severe neuromuscular disease is characterized by a degeneration and loss of alpha motor neurons of the spinal cord anterior horn cells, which results in progressive symmetrical weakness, atrophy of the proximal voluntary muscles, and infant death.
Two most identical copies of SMN gene, telomeric SMN (SMN1) and centromeric SMN (SMN2), have been identified. These two SMN genes are highly homologous and differing in only five nucleotide exchanges within their 3’ regions. These variations do not alter the encoded amino acids. These nucleotide differences located in exons 7 and 8, allow SMN1 gene to be distinguished from SMN2 gene.
It has been reported that more than 95% of SMA patients were homozygous deletion of SMN1 gene. Therefore, the detection of the absence of SMN1 can be a useful tool for SMA diagnosis. Furthermore, because of the high incidence of SMA, the high carrier frequency of at least 1 in 50, the severity of the disease in the patients, and the lack of effective of treatment, carrier testing for SMN1 deletion is an important question in genetic counseling. However, a highly homologous SMN2 gene also exits and hampers the detection of the loss of SMN1 which makes the detection of SMA carrier test difficult.
Here, we present a new, rapid, simple and high reliable method to detect the SMN1 deletion and to determine the copy number of the SMN1 and SMN2 by denaturing high-performance liquid chromatography (DHPLC). DHPLC is a novel, simple, fast and non gel-base method that is very sensitive and specific for detection DNA variations. Furthermore, we describe a multiplex PCR strategy to determine the SMN1 and SMN2 genes copy number in order to avoid bias due to fluctuations in the copy number of SMN genes. The assay uses the X-linked CYBB gene and KRIT1 gene as standards to determine the relative gene dosage of SMN1 and SMN2 genes. We demonstrate that this assay is able to accurately distinguish 2 gene copies from 4 gene copies and it can identify SMA carriers and normal populations by the accurate determination of SMN copy number.
This project will contribute to apply this novel, fast, and reliable tool for diagnosis of SMA and carrier detection of SMN1 and SMN2 genes by using DHPLC system.
| Study Type : | Observational |
| Enrollment : | 500 participants |
| Observational Model: | Case Control |
| Primary Purpose: | Screening |
| Time Perspective: | Longitudinal |
| Time Perspective: | Prospective |
| Official Title: | Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System: Establishing a Novel Highly Efficient and Reliable SMA Carrier Screening Test |
| Study Start Date : | April 2004 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Clinical diagnosis of Spinal muscular atrophy
Exclusion Criteria:
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00155168
| Contact: Yi-Ning su, MD,PhD | 886-2-23123456 ext 7675 | ynsu@ntumc.org |
| Taiwan | |
| Dept of Medical Genetics;National Taiwan University Hospital | Recruiting |
| Taipei, Taiwan, 100 | |
| Contact: Yi-Ning su, MD,PhD 886-2-23123456 ext 7675 ynsu@ntumc.org | |
| Study Chair: | Yi-Ning su, MD,PhD | National Taiwan University Hospital |
| ClinicalTrials.gov Identifier: | NCT00155168 History of Changes |
| Other Study ID Numbers: |
9361700452 |
| First Posted: | September 12, 2005 Key Record Dates |
| Last Update Posted: | September 12, 2005 |
| Last Verified: | April 2004 |
Keywords provided by National Taiwan University Hospital:
|
Spinal muscular atrophy (SMA) SMN1/SMN2 gene denaturing high-performance liquid chromatography (DHPLC) |
multiplex PCR gene dose carrier test |
Additional relevant MeSH terms:
|
Atrophy Muscular Atrophy Muscular Atrophy, Spinal Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases |
Signs and Symptoms Spinal Cord Diseases Central Nervous System Diseases Motor Neuron Disease Neurodegenerative Diseases Neuromuscular Diseases |